Similar articles

• Antiproliferative effects of low molecular weight heparin.

  Fletcher JP, Ao PY, Hawthorne WJ. Fletcher JP, et al. ANZ J Surg. 2004 Sep;74(9):793-6. doi: 10.1111/j.1445-1433.2004.03147.x. ANZ J Surg. 2004. PMID: 15379813
• A new model to assess the haemorrhagic potential of various heparin preparations.

  Berstad A, Bang CJ, Talstad I. Berstad A, et al. Acta Chir Scand Suppl. 1990;556:62-7. Acta Chir Scand Suppl. 1990. PMID: 1963019
• Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.

  Ajayi AA, Pharmacols FB, Cooper J, Horn EH, Rubin PC. Ajayi AA, et al. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):539-45. doi: 10.1358/mf.2007.29.8.1116308. Methods Find Exp Clin Pharmacol. 2007. PMID: 18040530
• Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine.

  Dietrich CP, Shinjo SK, Moraes FA, Castro RA, Mendes A, Gouvea TC, Nader HB. Dietrich CP, et al. Semin Thromb Hemost. 1999;25 Suppl 3:43-50. Semin Thromb Hemost. 1999. PMID: 10549715 Review.
• Differentiation of the low-molecular-weight heparins.

  Racine E. Racine E. Pharmacotherapy. 2001 Jun;21(6 Pt 2):62S-70S; discussion 71S-72S. doi: 10.1592/phco.21.8.62s.34594. Pharmacotherapy. 2001. PMID: 11401195 Review.